GlassScriptPhysician profile
Suzanne A Sorof
NPI 1942393004
$28,658.84
in general payments reported to CMS, 2019-2025
37 companies · $2,717 in 2025
The $2,717 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,829 · 2020: $3,312 · 2021: $5,751 · 2022: $6,082 · 2023: $855 · 2024: $5,113 · 2025: $2,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $2,905 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $2,905.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $14,146.11 | 2019-2024 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $6,547.87 | 2022-2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $2,017.68 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $1,298.52 | 2019 | |
| Amgen INC. | $486.14 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $453.84 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $372.69 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $340.05 | 2019-2024 | Lifevest |
| Abbott Laboratories | $326.95 | 2019-2024 | Cardiomems, Amplatzer Talisman |
| Philips North America LLC | $266.00 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.13 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $211.16 | 2019-2023 | Camzyos |
| Pfizer INC. | $207.89 | 2019-2025 | |
| Ekos Corporation | $159.42 | 2019 | |
| Abiomed | $151.74 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $142.24 | 2023-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $132.77 | 2022-2024 | Wainua, Farxiga |
| Impulse Dynamics (USA) INC. | $123.37 | 2022 | |
| Alnylam Pharmaceuticals INC. | $120.74 | 2022-2024 | Amvuttra |
| Boston Scientific Corporation | $102.89 | 2019-2024 | |
| Inspire Medical Systems, INC. | $96.52 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $94.55 | 2019-2022 | |
| Medtronic Vascular, INC. | $88.24 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $76.99 | 2021-2023 | Arcalyst |
| Zoll Respicardia, INC. | $67.82 | 2023-2024 | Remede System |
| Merck Sharp & Dohme LLC | $49.99 | 2021-2022 | |
| Astellas Pharma US INC | $43.93 | 2019-2022 | |
| Gilead Sciences, INC. | $39.41 | 2019 | |
| Irhythm Technologies, INC. | $39.27 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Teleflex LLC | $33.42 | 2024 | Quikclot |
| Lundbeck LLC | $32.88 | 2019 | |
| Itamar Medical INC | $32.54 | 2021-2022 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 | |
| Cvrx, INC. | $24.50 | 2024 | Barostim Neo System |
| Amarin Pharma, INC. | $18.60 | 2020 | |
| Chiesi USA, INC. | $17.92 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $17.06 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Sorof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.